Aldehyde dehydrogenase 2 Glu504Lys variant predicts a worse prognosis of acute coronary syndrome patients
Open Access
- 1 April 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (4), 2518-2522
- https://doi.org/10.1111/jcmm.13536
Abstract
Aldehyde dehydrogenase 2 (ALDH2) Glu504Lys variant was an independent risk factor for acute coronary syndrome (ACS). However, there are lacking researches about the relationship between the variant and prognosis of ACS. In the prospective study, 377 ACS patients were grouped into the wild-type (*1/*1) and the mutation (*2/*2 + *1/*2) groups according to genotype detection. Compared with the wild-type group, incidences of major adverse cardiac events (MACE) and cardiac death were both higher in the mutation group (9.2% vs 21.0%, P = .002; 5.2% vs 12.2%, P = .026); the MACE-free and the cardiac-death-free cumulative survival rates were obviously lower in the mutation group. Moreover, the mutant genotypes were associated with significantly increased risk of MACE and cardiac death (HR 2.443, 95%CI: 1.390-4.296, P = .002; HR 2.727, 95%CI: 1.303-5.708, P = .008). These results suggested that ALDH2 Glu504Lys variant could predict a worse prognosis of ACS patients.Keywords
Funding Information
- National Natural Science Foundation of China (81571934, 81570401, 81601717)
This publication has 15 references indexed in Scilit:
- Susceptibility loci for metabolic syndrome and metabolic components identified in Han Chinese: a multi‐stage genome‐wide association studyJournal of Cellular and Molecular Medicine, 2017
- Inhibition of ALDH2 by O-GlcNAcylation contributes to the hyperglycemic exacerbation of myocardial ischemia/reperfusion injuryOncotarget, 2016
- Aldehyde dehydrogenase 2 inhibits inflammatory response and regulates atherosclerotic plaqueOncotarget, 2016
- Variant Aldehyde Dehydrogenase 2 ( ALDH2*2 ) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial InfarctionJournal of the American Heart Association, 2016
- Mitochondrial Aldehyde Dehydrogenase 2 Plays Protective Roles in Heart Failure After Myocardial Infarction via Suppression of the Cytosolic JNK/p53 Pathway in MiceJournal of the American Heart Association, 2014
- Targeting Aldehyde Dehydrogenase 2: New Therapeutic OpportunitiesPhysiological Reviews, 2014
- Acetylation‐dependent regulation of mitochondrial ALDH2 activation by SIRT3 mediates acute ethanol‐induced eNOS activationFEBS Letters, 2011
- Genome-wide association study of coronary artery disease in the JapaneseEuropean Journal of Human Genetics, 2011
- Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndromeJournal of Cellular and Molecular Medicine, 2010
- Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the HeartScience, 2008